Change of centrotemporal spikes from onset to remission in self-limited epilepsy with centrotemporal spikes (SLECTS)

Han, Ji Yeon; Choi, Sun Ah; Chung, Yoon Young; Shim, Young Kyu; Kim, Woo Joong; Kim, Soo Yeon; Kim, Hunmin; Lim, Byung Chan; Chae, Jong Hee; Choi, Jieun; Kim, Ki Joong

doi:10.1016/j.braindev.2019.11.005

Cited by 5 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Usually, it is until the age of 13 years that improvement can be observed in EEG results [19,20]. Treatment did not shorten the time of spike persistence in the three groups [21]. During the follow-up period of our study, EEG results suggested that no drugs significantly reduced rolandic discharges.…”

Section: Discussionmentioning

confidence: 50%

Outcome analysis of children with rolandic discharges on EEG: A real-world study

Chen

Tian

et al. 2020

Seizure

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 50%

Outcome analysis of children with rolandic discharges on EEG: A real-world study

Chen

Tian

et al. 2020

Seizure

View full text Add to dashboard Cite

“…A retrospective study ( Kim, et al, 2018 ) compared the EEG of BECTS with matched onset age in the two groups and found no difference in the abnormal EEG duration between treated with ASMs and untreated children, which indicated that ASM treatment did not shorten the duration of EEG abnormalities. Another retrospective study ( Han, et al, 2020 ) also found that treatment with OXC in BECTS did not affect the pattern of spike disappearance. However, other studies ( Kanemura, et al, 2018 ; Tacke, et al, 2018 ) demonstrated that ASM treatment in BECTS might have a positive effect on EEG.…”

Section: Discussionmentioning

confidence: 91%

“…There has been a long debate about whether ASM use might promote EEG changes in patients with BECTS ( Tenney et al, 2016 ; Kim, et al, 2018 ; Tacke, et al, 2018 ; Han et al, 2020 ). A retrospective study ( Kim, et al, 2018 ) compared the EEG of BECTS with matched onset age in the two groups and found no difference in the abnormal EEG duration between treated with ASMs and untreated children, which indicated that ASM treatment did not shorten the duration of EEG abnormalities.…”

Section: Discussionmentioning

confidence: 99%

Anti-Seizure Medication Treatment of Benign Childhood Epilepsy With Centrotemporal Spikes: A Systematic Review and Meta-analysis

Wei¹,

Yang²,

Chen³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: This study aimed to evaluate the efficacy and tolerability of Anti-Seizure medication (ASM) treatment in patients with BECTS.Method: We searched PubMed, Cochrane Library, Embase, MEDLINE, Web of Science, China National Knowledge Infrastructure (CNKI), WANFANG DATA, and China Science and Technology Journal Database (VIP) between 1 Jan 1990, and 1 Sep 2021, for randomized controlled studies. Data on seizure freedom rate, rate of treatment withdrawal due to serious adverse events, rate of any adverse events and dropout, 50% remission rate, the proportion of patients whose EEG to be normalized, and improvement in cognitive function were extracted by two authors independently. The pooled data were meta-analyzed using a random effects model.Results: A total of 27 studies evaluating 9 ASMs were included, 19 of which were suitable for meta-analysis. Compared with sulthiame (STM), levetiracetam (LEV) was associated with a higher probability of treatment withdrawal due to serious adverse events [RR = 5.12, 95% CI (1.19, 22.01), I2 = 0.0%], experiencing any adverse events [RR = 5.12, 95% CI (1.19, 22.01)], and dropping out for any reason [RR = 3.17, 95% CI (1.36, 10.11)], while it did not affect the seizure freedom rate [RR = 0.90, 95% CI (0.75, 1.06)]. LEV significantly improved cognitive performance relative to carbamazepine (CBZ) but had no effect on the proportion of any adverse events [RR = 0.62, 95% CI (0.25, 1.59)] and EEG to be normalized [RR = 1.27, 95% CI (0.94, 1.71)]. There was no higher probability of a 50% remission rate when comparing valproic acid (VPA) to LEV [RR = 0.96, 95% CI (0.57, 1.61)] and oxcarbazepine (OXC) [RR = 0.61, 95% CI (0.31, 1.20)]. In addition, STM was related to a higher probability of EEG normalization than placebo [RR = 4.61, 95% CI (2.12, 10.01)]. The included single studies also provided some evidence for the efficacy and/or tolerability of other ASMs in BECTS, including topiramate, lamotrigine, clobazam, and clonazepam. The risk of bias of the included studies was frequently low or unclear.Conclusion: This study indicated some discrepancies in efficacy and tolerability among ASMs used in patients with BECTS. More randomized controlled trials (RCTs) comparing ASMs with larger populations are required to ascertain the optimum antiepileptic drug treatment to guide clinicians.

show abstract

“…However, as in our study population, retention of centrotemporal spikes on EEG is observed for a much longer period (more than 3 years after the last seizure, on average). 4…”

Section: Discussionmentioning

confidence: 99%

“…Certain patients are treated with anti-seizure medication (ASM) whereas others are only observed. 3,4 Ideally, treatment of CECTS should suppress seizures and prevent evolution to atypical forms. 5–7 However, nearly all ASMs cause adverse effects that range in severity from sleep disturbance, irritability, mood changes, and stomach upset to progressive impairment like aplastic anemia or hepatic failure.…”

Section: Introductionmentioning

confidence: 99%

Comparative assessment of health-related quality of life with and without anticonvulsant therapy in patients with childhood epilepsy with centrotemporal spikes

Nagae

Aringazina

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

Objective To estimate anti-seizure medication (ASM) treatment burden and its effects on health-related quality of life (HRQOL) in new-onset childhood epilepsy with centrotemporal spikes (CECTS) using different treatment approaches in Kazakhstan. Methods Forty-three patients were followed prospectively during 2015 to 2020 for at least 2 years. Patients were divided into three groups: (1) history of ≤3 seizures (n = 32); (2) ≥4 seizures (n = 6); (3) cerebral palsy coexisting with CECTS (n = 5). The first group was subdivided into treated (n = 8) and observed (n = 24) subgroups. The shortened Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55) was completed by parents after 6 months of follow-up. Results At the end of the study, all children had a sustained remission from seizures for at least 2 years. Differences were identified in emotional, social, and physical subscales between patients in the low seizure frequency group. Signs of low self-esteem, anxiety, depression, limited social interaction owing to pharmacotherapy, painful medical procedures, and stigma were reasons for decreased HRQOL in the treated subgroup. Overall HRQOL in treated (89.2 ± 5.2) patients was significantly decreased compared with observed children with low seizure frequency (98.0 ± 3.0). Conclusion ASM therapy does not necessarily improve and may decrease HRQOL in children with low seizure frequency CECTS.

show abstract

Change of centrotemporal spikes from onset to remission in self-limited epilepsy with centrotemporal spikes (SLECTS)

Cited by 5 publications

References 20 publications

Outcome analysis of children with rolandic discharges on EEG: A real-world study

Outcome analysis of children with rolandic discharges on EEG: A real-world study

Anti-Seizure Medication Treatment of Benign Childhood Epilepsy With Centrotemporal Spikes: A Systematic Review and Meta-analysis

Comparative assessment of health-related quality of life with and without anticonvulsant therapy in patients with childhood epilepsy with centrotemporal spikes

Contact Info

Product

Resources

About